Vitrolife AB (publ) (VITR.ST)
SEK 168.1
(-1.87%)
SEK 168.1
(-1.87%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -28.44 SEK | -1077.32% |
| 2022 | 2.91 SEK | -2.02% |
| 2021 | 2.97 SEK | 12.5% |
| 2020 | 2.64 SEK | -25.21% |
| 2019 | 3.53 SEK | 23.86% |
| 2018 | 2.85 SEK | 17.28% |
| 2017 | 2.43 SEK | 38.86% |
| 2016 | 1.75 SEK | 4.17% |
| 2015 | 1.68 SEK | 54.13% |
| 2014 | 1.09 SEK | 91.23% |
| 2013 | 0.57 SEK | -83.28% |
| 2012 | 3.41 SEK | 1000.0% |
| 2011 | 0.31 SEK | 3.33% |
| 2010 | 0.30 SEK | -14.29% |
| 2009 | 0.35 SEK | 16.67% |
| 2008 | 0.30 SEK | -16.67% |
| 2007 | 0.36 SEK | 140.0% |
| 2006 | 0.15 SEK | -6.25% |
| 2005 | 0.16 SEK | 14.29% |
| 2004 | 0.14 SEK | -71.43% |
| 2003 | 0.49 SEK | -61.42% |
| 2002 | 1.27 SEK | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q2 | 1.06 SEK | 24.71% |
| 2024 Q1 | 0.85 SEK | 102.75% |
| 2024 Q3 | 0.85 SEK | -18.87% |
| 2023 FY | - SEK | -1077.32% |
| 2023 Q1 | 0.74 SEK | 34.55% |
| 2023 Q2 | 0.78 SEK | 5.41% |
| 2023 Q3 | 0.90 SEK | 15.38% |
| 2023 Q4 | -30.87 SEK | -3530.0% |
| 2022 Q2 | 0.96 SEK | 57.38% |
| 2022 Q1 | 0.61 SEK | 90.62% |
| 2022 Q3 | 0.80 SEK | -16.67% |
| 2022 Q4 | 0.55 SEK | -31.25% |
| 2022 FY | - SEK | -2.02% |
| 2021 Q1 | 1.09 SEK | 10.1% |
| 2021 Q2 | 0.79 SEK | -27.52% |
| 2021 Q4 | 0.32 SEK | -64.04% |
| 2021 FY | - SEK | 12.5% |
| 2021 Q3 | 0.89 SEK | 12.66% |
| 2020 Q4 | 0.99 SEK | 22.22% |
| 2020 FY | - SEK | -25.21% |
| 2020 Q2 | 0.11 SEK | -85.14% |
| 2020 Q3 | 0.81 SEK | 636.36% |
| 2020 Q1 | 0.74 SEK | -16.85% |
| 2019 Q3 | 0.98 SEK | 12.64% |
| 2019 Q4 | 0.89 SEK | -9.18% |
| 2019 Q2 | 0.87 SEK | 10.13% |
| 2019 FY | - SEK | 23.86% |
| 2019 Q1 | 0.79 SEK | 2.6% |
| 2018 Q4 | 0.77 SEK | 11.59% |
| 2018 Q2 | 0.73 SEK | 10.61% |
| 2018 Q3 | 0.69 SEK | -5.48% |
| 2018 Q1 | 0.66 SEK | 4.76% |
| 2018 FY | - SEK | 17.28% |
| 2017 Q4 | 0.63 SEK | 5.0% |
| 2017 FY | - SEK | 38.86% |
| 2017 Q2 | 0.66 SEK | 20.0% |
| 2017 Q1 | 0.55 SEK | 0.0% |
| 2017 Q3 | 0.60 SEK | -9.09% |
| 2016 Q3 | 0.41 SEK | -6.82% |
| 2016 FY | - SEK | 4.17% |
| 2016 Q1 | 0.35 SEK | -33.96% |
| 2016 Q2 | 0.44 SEK | 25.71% |
| 2016 Q4 | 0.55 SEK | 34.15% |
| 2015 FY | - SEK | 54.13% |
| 2015 Q4 | 0.53 SEK | 10.42% |
| 2015 Q1 | 0.32 SEK | 10.34% |
| 2015 Q2 | 0.35 SEK | 9.37% |
| 2015 Q3 | 0.48 SEK | 37.14% |
| 2014 Q2 | 0.23 SEK | 4.55% |
| 2014 Q1 | 0.22 SEK | 46.67% |
| 2014 FY | - SEK | 91.23% |
| 2014 Q4 | 0.29 SEK | -19.44% |
| 2014 Q3 | 0.36 SEK | 56.52% |
| 2013 FY | - SEK | -83.28% |
| 2013 Q2 | 0.12 SEK | 0.0% |
| 2013 Q1 | 0.12 SEK | -96.13% |
| 2013 Q3 | 0.17 SEK | 41.67% |
| 2013 Q4 | 0.15 SEK | -11.76% |
| 2012 FY | - SEK | 1000.0% |
| 2012 Q3 | 0.09 SEK | -33.85% |
| 2012 Q4 | 3.10 SEK | 3504.65% |
| 2012 Q1 | 0.09 SEK | 343.4% |
| 2012 Q2 | 0.13 SEK | 38.3% |
| 2011 Q1 | 0.09 SEK | 1134.48% |
| 2011 FY | - SEK | 3.33% |
| 2011 Q4 | 0.02 SEK | -78.37% |
| 2011 Q3 | 0.10 SEK | -2.0% |
| 2011 Q2 | 0.10 SEK | 11.11% |
| 2010 Q1 | 0.10 SEK | -9.09% |
| 2010 Q2 | 0.10 SEK | -4.0% |
| 2010 Q3 | 0.11 SEK | 14.58% |
| 2010 Q4 | -0.01 SEK | -107.91% |
| 2010 FY | - SEK | -14.29% |
| 2009 FY | - SEK | 16.67% |
| 2009 Q2 | 0.08 SEK | 0.0% |
| 2009 Q4 | 0.11 SEK | 48.65% |
| 2009 Q3 | 0.07 SEK | -2.63% |
| 2008 FY | - SEK | -16.67% |
| 2007 FY | - SEK | 140.0% |
| 2006 FY | - SEK | -6.25% |
| 2005 FY | - SEK | 14.29% |
| 2004 FY | - SEK | -71.43% |
| 2003 FY | - SEK | -61.42% |
| 2002 FY | - SEK | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| Acarix AB (publ) | -0.16 SEK | -17675.0% |
| ADDvise Group AB (publ) | 0.56 SEK | 5178.571% |
| ADDvise Group AB (publ) | 0.56 SEK | 5178.571% |
| Arcoma AB | 0.19 SEK | 15068.421% |
| Bactiguard Holding AB (publ) | -3.95 SEK | -620.0% |
| BICO Group AB (publ) | -12.99 SEK | -118.938% |
| Boule Diagnostics AB (publ) | 0.64 SEK | 4543.75% |
| CellaVision AB (publ) | 5.46 SEK | 620.879% |
| Clinical Laserthermia Systems AB (publ) | -23.76 SEK | -19.697% |
| Chordate Medical Holding AB (publ) | -0.13 SEK | -21776.923% |
| C-Rad AB (publ) | 1.05 SEK | 2808.571% |
| Duearity AB (publ) | -0.40 SEK | -7010.0% |
| Dignitana AB (publ) | -0.25 SEK | -11276.0% |
| Episurf Medical AB (publ) | -0.36 SEK | -7800.0% |
| Getinge AB (publ) | 8.86 SEK | 420.993% |
| Scandinavian Real Heart AB (Publ) | -0.70 SEK | -3962.857% |
| Iconovo AB (publ) | -4.39 SEK | -547.836% |
| Integrum AB (publ) | 0.23 SEK | 12465.217% |
| Luxbright AB (publ) | -0.37 SEK | -7586.486% |
| Mentice AB (publ) | -0.11 SEK | -25754.545% |
| OssDsign AB (publ) | -1.59 SEK | -1688.679% |
| Paxman AB (publ) | 0.44 SEK | 6563.636% |
| Promimic AB (publ) | -0.50 SEK | -5588.0% |
| Qlife Holding AB (publ) | -526.52 SEK | 94.598% |
| SciBase Holding AB (publ) | -0.51 SEK | -5476.471% |
| ScandiDos AB (publ) | -0.32 SEK | -8787.5% |
| Sectra AB (publ) | 2.22 SEK | 1381.081% |
| Sedana Medical AB (publ) | -0.60 SEK | -4640.0% |
| Senzime AB (publ) | -1.45 SEK | -1861.379% |
| SpectraCure AB (publ) | -0.21 SEK | -13442.857% |
| Stille AB | 5.31 SEK | 635.593% |
| Xvivo Perfusion AB (publ) | 3.07 SEK | 1026.384% |